Tumor-infiltrating HLA-matched CD4+ T cells retargeted against Hodgkin and Reed-Sternberg cells
Hodgkin lymphoma (HL) presents with a unique histologic pattern. Pathognomonic Hodgkin and Reed-Sternberg (HRS) cells usually account for less than 1% of the tumor and are embedded in a reactive infiltrate mainly comprised of CD4 + T cells. HRS cells induce an immunosuppressive microenvironment and...
Gespeichert in:
Veröffentlicht in: | Oncoimmunology 2016-06, Vol.5 (6), p.e1160186-e1160186 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Hodgkin lymphoma (HL) presents with a unique histologic pattern. Pathognomonic Hodgkin and Reed-Sternberg (HRS) cells usually account for less than 1% of the tumor and are embedded in a reactive infiltrate mainly comprised of CD4
+
T cells. HRS cells induce an immunosuppressive microenvironment and thereby escape antitumor immunity. To investigate the impact of interactions between HRS cells and T cells, we performed long-term co-culture studies that were further translated into a xenograft model. Surprisingly, we revealed a strong antitumor potential of allogeneic CD4
+
T cells against HL cell lines. HRS and CD4
+
T cells interact by adhesion complexes similar to immunological synapses. Tumor-cell killing was likely based on the recognition of allogeneic major histocompatibility complex class II (MHC-II) receptor, while CD4
+
T cells from MHC-II compatible donors did not develop any antitumor potential in case of HL cell line L428. However, gene expression profiling (GEP) of co-cultured HRS cells as well as tumor infiltration of matched CD4
+
T cells indicated cellular interactions. Moreover, matched CD4
+
T cells could be activated to kill CD30
+
HRS cells when redirected with a CD30-specific chimeric antigen receptor. Our work gives novel insights into the crosstalk between HRS and CD4
+
T cells, suggesting the latter as potent effector cells in the adoptive cell therapy of HL. |
---|---|
ISSN: | 2162-4011 2162-402X 2162-402X |
DOI: | 10.1080/2162402X.2016.1160186 |